Keegan S Johnson1, Flora Levin, Davis S Chu. 1. Department of Ophthalmology and Visual Science New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.
Abstract
PURPOSE: To report a case of persistent corneal epithelial erosion in a patient undergoing treatment with erlotinib for her lung cancer. METHODS: Report of a 79-year-old woman who presented with a persistent corneal epithelial defect associated with infectious keratitis that waxed and waned for 5 months despite treatment. She had been diagnosed with lung cancer and was being treated with erlotinib, a reversible epidermal growth factor receptor (EGFR) inhibitor. RESULTS: The keratitis required a biopsy to establish the diagnosis of Staphylococcus epidermidis keratitis. The infectious keratitis was successfully treated; however, her pain and the epithelial defect persisted. She discontinued the erlotinib treatment. Within 2 weeks, the abrasion healed and had no recurrence. CONCLUSIONS: This report is, to our knowledge, the first description of a nonhealing corneal erosion and infectious keratitis possibly associated with erlotinib toxicity. EGFR is expressed in basal epithelial cells across the cornea and limbal basal cells; it is considered imperative for corneal epithelial cell proliferation and wound healing. Erlotinib is mediated through inhibition of EGFR, which is a highly promising area in molecularly targeted chemotherapies. It will become increasingly important for ophthalmologists to recognize and treat side effects of chemotherapies interfering with the epithelial growth factor pathway.
PURPOSE: To report a case of persistent corneal epithelial erosion in a patient undergoing treatment with erlotinib for her lung cancer. METHODS: Report of a 79-year-old woman who presented with a persistent corneal epithelial defect associated with infectious keratitis that waxed and waned for 5 months despite treatment. She had been diagnosed with lung cancer and was being treated with erlotinib, a reversible epidermal growth factor receptor (EGFR) inhibitor. RESULTS: The keratitis required a biopsy to establish the diagnosis of Staphylococcus epidermidis keratitis. The infectious keratitis was successfully treated; however, her pain and the epithelial defect persisted. She discontinued the erlotinib treatment. Within 2 weeks, the abrasion healed and had no recurrence. CONCLUSIONS: This report is, to our knowledge, the first description of a nonhealing corneal erosion and infectious keratitis possibly associated with erlotinibtoxicity. EGFR is expressed in basal epithelial cells across the cornea and limbal basal cells; it is considered imperative for corneal epithelial cell proliferation and wound healing. Erlotinib is mediated through inhibition of EGFR, which is a highly promising area in molecularly targeted chemotherapies. It will become increasingly important for ophthalmologists to recognize and treat side effects of chemotherapies interfering with the epithelial growth factor pathway.
Authors: C Wertheimer; R Liegl; M Kernt; W Mayer; D Docheva; A Kampik; K H Eibl-Lindner Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-01-18 Impact factor: 3.117
Authors: Joanne L Peterson; Eric D Phelps; Mark A Doll; Shlomit Schaal; Brian P Ceresa Journal: Invest Ophthalmol Vis Sci Date: 2014-05-01 Impact factor: 4.799
Authors: Nagham Al-Zubidi; Dan S Gombos; David S Hong; Vivek Subbiah; Siqing Fu; Jordi Rodon Ahnert; Sarina A Piha-Paul; Apostolia M Tsimberidou; Daniel D Karp; Funda Meric Bernstam; Aung Naing Journal: Oncologist Date: 2021-04-08